Pepsodent's Germ Protection Campaigns: A Comparative-Advertising Case Study in the Indian Oral Care Market

Industry & Competitive Context

The Indian oral care category has, for decades, been a duopoly-with-challengers structure dominated by Colgate-Palmolive (India) Ltd. and Hindustan Unilever Limited (HUL, formerly Hindustan Lever Limited), with regional and value players occupying the price-sensitive segment. Colgate entered India in 1917 and incorporated a local subsidiary in 1937, giving it a multi-decade head start and near-monopoly positioning in dental cream before liberalization-era competition intensified. By 2013, court filings in Colgate Palmolive (India) Ltd. v. Hindustan Unilever Ltd. recorded that <cite index="25-1">Colgate was the market leader with more than 50% market share amongst all toothpastes, with Colgate Strong Teeth alone holding approximately 30% market share both by value and by volume in 2013</cite>. A trade-press account of the same dispute similarly reported that Colgate held a <cite index="31-1">54.2% market share in what was then described as the roughly Rs 5,050 crore Indian toothpaste market</cite>. Within HUL's portfolio, Pepsodent has been positioned as the company's principal "germ protection" challenger brand against Colgate's "cavity/strength" positioning, with Closeup addressing a separate, younger-skewing freshness segment. As of 2024, Hindustan Unilever's overall share of the Indian toothpaste market was reported at approximately 23%, according to the Grokipedia compilation of industry figures — a source that, while not a primary filing, aggregates multiple secondary reports and should be treated as indicative rather than fully verified.

Brand Situation Prior to Campaign

Pepsodent originated as an American brand launched in the United States in 1915 by the Pepsodent Company of Chicago, built around a formula containing pepsin and later marketed heavily on the "Irium" (sodium lauryl sulfate) ingredient story and the "You'll wonder where the yellow went" jingle, popularized through radio sponsorship of programs such as Amos 'n' Andy and The Pepsodent Show Starring Bob Hope. Unilever acquired the Pepsodent Company in 1944 and has continued to own the brand outside the United States and Canada, having sold the North American rights to Church & Dwight in 2003.

In India, Hindustan Unilever's own brand page states that <cite index="5-1">Pepsodent was launched in 1992 in India, and has since raised the benchmark on oral care solutions in the country, with a range of toothpaste and toothbrushes addressing specific oral care needs</cite>. HUL further states that <cite index="5-1">Pepsodent has, for the last 30 years, positioned itself as an expert in fighting germs — described as the root cause of oral issues such as bad breath, gum problems and cavities — and that it was the first toothpaste in India with an anti-germ formula containing fluoride</cite>. This company-stated history establishes germ protection, rather than whitening or cosmetic benefit, as Pepsodent's foundational and enduring positioning pillar in the Indian market from launch onward.

Court records from the 1997 dispute (detailed in Section 4) independently corroborate that HUL's advertising strategy in the mid-1990s centered on a "Germ check formula" narrative, with the company's own submissions referencing testing conducted at the Hindustan Lever Dental Research Centre.

Strategic Objective

Litigation records and HUL's own public statements indicate a consistent strategic objective across three decades: to displace Colgate's category leadership by making germ-fighting efficacy — rather than cavity prevention or whitening — the primary axis of competitive comparison, and to do so through direct or near-direct comparative advertising naming or clearly alluding to Colgate. This is documented across two major legal disputes, roughly sixteen years apart, both centered on numerical germ-protection superiority claims (Section 4).

Campaign Architecture & Execution

The "102% Better" Campaign (1997)

In 1997, HUL launched "New Pepsodent" with advertising claiming superior germ-fighting performance. According to the Supreme Court of India's judgment in Hindustan Lever Ltd. v. Colgate Palmolive (I) Ltd., the campaign asserted that <cite index="11-1">HLL's "New Pepsodent" toothpaste was "102% better than the leading toothpaste" based on germ-killing ability</cite>. The advertisement's execution, as described in the judgment, used a side-by-side visual device: it <cite index="11-1">depicted a schematic picture of saliva samples, showing one side with germs remaining after brushing with "the leading toothpaste" and the other showing negligible germs after use of "New Pepsodent," while also citing tests conducted at the Hindustan Lever Dental Research Centre and describing the product's "Germ check formula" as twice as effective as, and 102% better in fighting germs than, the leading toothpaste</cite>. The television execution went further: <cite index="11-1">it showed two boys being asked which toothpaste they had used that morning, with one clearly naming Pepsodent while the other's muted, lip-synced response was widely read by viewers as "Colgate," reinforced by a jingle resembling Colgate's own</cite>.

Colgate filed a complaint with the Monopolies and Restrictive Trade Practices Commission (MRTPC) on 15 October 1997, alleging disparagement, and <cite index="10-1">HUL in turn filed a counter-complaint against Colgate's own "Suraksha Chakra" advertising on 22 October 1997</cite>. The MRTPC granted a temporary injunction, which HUL appealed; the Supreme Court, in its judgment of 17 December 1997, upheld the Commission's approach, characterizing the injunction as an interim measure pending expert evaluation of the conflicting laboratory claims of both parties, and did not find grounds to interfere with it. The Commission separately declined to impose a "total ban" on Colgate's Suraksha Chakra advertising, a refusal that HUL had also appealed. Both cross-appeals were before the Supreme Court together in 1999.

The Rural and Value Architecture: Sachets and Pricing (mid-to-late 1990s)

Independent of the litigation record, a business-history account (LinkedIn, sourced from secondary industry commentary rather than a primary filing) describes HUL's parallel distribution and pricing execution during this period: door-to-door sampling by salespeople offering free Pepsodent with other HUL products, and the introduction of a patented toothpaste sachet priced far below tube formats to widen penetration among price-sensitive households. Because this account is a secondary compilation rather than a company filing or court record, it is presented here as reported commentary and not as independently verified fact; no company press release or annual report was located confirming the specific sachet pricing figures.

The "130% Germ Attack Power" Campaign (2013)

In August 2013, HUL relaunched a comparative campaign for "Pepsodent Germicheck Superior Power" (Pepsodent GSP). Delhi High Court records describe a television commercial and print advertisement in which <cite index="26-1">HUL claimed Pepsodent GSP to be 130% better than Colgate Dental Cream Strong Teeth (Colgate ST)</cite>. The television execution, per the court's description, depicted <cite index="25-1">two boys undergoing what the advertisement termed a "preventive cavity test," with the "Colgate boy" shown failing the test and the "Pepsodent boy" passing, concluding with a voiceover asserting that Pepsodent was 130% better than Colgate, with Colgate Strong Teeth indexed at 100%</cite>. The print advertisement, which the court noted <cite index="25-1">ran on the front page of the Hindustan Times' New Delhi edition on 11 August 2013</cite>, used the tagline "Pepsodent now better than Colgate Strong Teeth" alongside the word "Attaaaack," and, per the appellate judgment, visually contrasted a distressed-looking Colgate child against a healthy-looking Pepsodent child.

Colgate filed suit on 13 August 2013 seeking an injunction. HUL's defense, as recorded in the judgment, argued that <cite index="14-1">the 130% claim was based on Colgate Strong Teeth's Triclosan concentration having been raised to 0.2% in response to Pepsodent's original launch, and that Pepsodent had subsequently increased its own Triclosan concentration to 0.2% and added fluoride, ultimately prompting Colgate itself to add fluoride and 0.2% Triclosan to Strong Teeth</cite> — a claim HUL's counsel used to argue that comparative pressure had benefited consumers through product improvement on both sides.

The Single Judge of the Delhi High Court dismissed Colgate's application for an interim injunction on 21 August 2013, a decision widely reported by trade media. On appeal, a Division Bench of the same court partially reversed this: it found the television commercial did not, on its own, disparage Colgate, but held that the specific <cite index="26-1">voiceover claim of "130% Germ Attack Power" was misleading and inaccurate, given that Colgate Total — a different product from Colgate Strong Teeth — was the one that delivered sustained release of Triclosan, and directed that the claim either be deleted or suitably modified to refer only to Colgate Strong Teeth</cite>. The Bench separately found the print advertisement to be prima facie disparaging and restrained its further publication. Trade outlet Exchange4media reported the ruling in similar terms, noting the court's finding that the advertisement's Hindi voiceover — <cite index="31-1">"Naya Pepsodent Germi Check Colgate Ke Mukable 130 Pratishat Germ Attack Power" ("In comparison to Colgate, New Pepsodent Germi Check has 130 per cent Germ Attack Power")</cite> — was misleading and had to be modified.

Other Campaign Elements Referenced in Non-Primary Sources

Multiple secondary marketing write-ups (student case studies, marketing blogs, and brand-strategy compilations) reference additional Pepsodent campaign elements over the years, including a "Dishum Dishum" campaign, a "Bhoot" (ghost) campaign encouraging night-time brushing among children, a "Pappu aur Papa" campaign featuring actor Shah Rukh Khan (reported to have been signed as brand ambassador in May 2010), and a "germ indicator" pack feature introduced around 2002. These references appear consistently across several independent secondary sources, which lends them some credibility as commonly reported brand history; however, none could be verified against a company press release, annual report, or credible news outlet meeting this case study's sourcing bar.

Positioning & Consumer Insight

Across both documented litigation episodes (1997 and 2013), Pepsodent's core positioning strategy was consistent: convert an intangible, hard-to-verify attribute — "germ-fighting" efficacy — into a specific, quantified, seemingly scientific number (102%, later 130%) benchmarked explicitly or implicitly against Colgate. This is a classic comparative-advertising tactic aimed at borrowing the market leader's salience: rather than building an independent value proposition, HUL's campaigns positioned Pepsodent relative to Colgate, using precise-sounding percentages to create an impression of clinical rigor. The Delhi High Court's own reasoning captured the strategic risk in this approach, observing that <cite index="26-1">the message that "Pepsodent GSP is better than Colgate ST in combating tooth decay" constituted a serious representation of fact rather than mere puffery, given the specificity of the numerical claim</cite>. In other words, the same precision that made the claim persuasive to consumers also made it legally vulnerable, since courts distinguish between generalized brand puffery (permissible) and specific, falsifiable factual claims (actionable if unsubstantiated).

HUL's own repeated framing of Pepsodent as an "expert in fighting germs" for "the last 30 years" — as stated on its official brand page — indicates that the germ-protection insight was treated as a durable brand asset rather than a campaign-specific device, reused and re-quantified across multiple product relaunches (Germicheck, Germicheck 8, Pepsodent GSP) over more than two decades.

Media & Channel Strategy

Verified public sources confirm television commercials and print advertising as the primary channels for both the 1997 and 2013 campaigns; the 2013 print execution specifically ran as a front-page advertisement in the Hindustan Times' New Delhi edition. No verified public information is available on total media spend, channel mix percentages, digital or outdoor allocation, or audience reach/frequency figures for either campaign, as none of the litigation records, HUL press materials, or credible news sources reviewed disclosed this data.

Separately, HUL's own current brand communications (via its official website) describe an ongoing "Germicheck 8 actions" formulation claimed to be <cite index="5-1">clinically proven to fight germs on teeth, cheeks, gums and tongue, offering eight scientifically proven benefits</cite>, indicating that the germ-protection narrative has persisted as a core product claim into the brand's contemporary marketing, independent of the specific comparative percentage claims litigated in 1997 and 2013.

Business & Brand Outcomes

Verified, court-recorded outcomes are limited but specific:

• In the 1997 dispute, the MRTPC's interim injunction against HUL's "102% better" claim was upheld by the Supreme Court as an appropriate interim measure pending expert verification; the matter was not conclusively adjudicated on the merits in the record reviewed, and Colgate's related complaint about HUL's advertising, and HUL's cross-complaint about Colgate's "Suraksha Chakra" campaign, were both before the court on cross-appeal.

  
  

• In the 2013 dispute, Colgate's plaint (as recorded in the judgment) stated that Pepsodent's market share had <cite index="14-1">dropped from 13.7% to 6%, with the specific Pepsodent GSP variant depicted in the advertisement holding a market share of only 0.2%, against Colgate's more-than-50% overall share and Colgate Strong Teeth's approximately 30% share in 2013</cite>. These are Colgate's own pleaded figures, presented to the court to support its case, and should be read as one party's litigation submission rather than independently audited market data; no company financial disclosure corroborating these exact figures was located.

  
  

• The Delhi High Court's Division Bench ultimately ordered HUL to modify the "130% Germ Attack Power" voiceover and restrained further publication of the print advertisement found to be disparaging, while declining to find the television commercial disparaging in its entirety.

Strategic Implications

The documented record across 1997 and 2013 illustrates a recurring strategic tension in FMCG comparative advertising: precise, quantified superiority claims ("102% better," "130% germ attack power") are more persuasive to consumers than generalized claims, but Indian courts have consistently treated such specificity as a factual assertion requiring substantiation, rather than as protected puffery. Both episodes show HUL adopting the same comparative architecture roughly sixteen years apart, only for a similar legal challenge and partial regulatory correction to recur. This suggests that whatever short-term attention or trial the campaigns generated came bundled with recurring legal, regulatory, and reputational costs — costs that are documented in the public record even where the offsetting commercial upside is not.

The case also demonstrates a structural asymmetry in comparative advertising against a category leader: as the "attacker" brand, Pepsodent had greater incentive to name or clearly reference Colgate, since doing so borrows the leader's salience; Colgate, as the incumbent, had comparatively less incentive to reciprocate directly and instead relied on regulatory and judicial channels (MRTPC, then Delhi High Court) to contain the challenger's claims. This dynamic — repeated litigation as a defensive tool for the incumbent, and repeated numerically specific comparative claims as an offensive tool for the challenger — is the clearest, most verifiable strategic pattern in the public record on Pepsodent's germ protection campaigns.

Discussion Questions

1. Courts distinguished between "puffery" (permissible exaggeration) and "a serious representation of fact" (actionable if false) largely based on the specificity of Pepsodent's percentage claims. From a brand strategy standpoint, what are the trade-offs between using a precise, quantified superiority claim versus a vaguer qualitative claim in comparative advertising?

   
   

2. HUL repeated a nearly identical comparative-claim architecture in 1997 and again in 2013, both times facing legal challenge. Based only on the documented outcomes, what might explain a company's willingness to reuse a strategy that had previously drawn regulatory and legal action?

   
   

3. Colgate's pleaded figures in the 2013 case claimed a sharp drop in Pepsodent's overall market share alongside a very low share for the specific GSP variant featured in the advertisement. If these figures are accurate, what does that suggest about the relationship between aggressive comparative advertising and actual market share gains for a challenger brand?

   
   

4. The Delhi High Court distinguished between the television commercial (not found disparaging) and the print advertisement (found disparaging) from the same 2013 campaign, despite both carrying the same "130%" claim. What does this suggest about how creative execution, and not just the underlying claim, shapes legal and consumer risk in comparative advertising?

   
   

5. Given the significant gaps in publicly verifiable data on media spend, campaign-level sales impact, and other campaigns often attributed to Pepsodent (e.g., "Dishum Dishum," "Bhoot"), what does this case suggest about the limitations of building marketing case studies primarily from litigation records rather than company disclosures?